NCT03250052

A Clinical Trial to Evaluate Pharmacokinetic Interactions and Safety Between Fimasartan and Linagliptin in Healthy Male Volunteers

A Phase I Clinical Trial to Evaluate Pharmacokinetic Interactions and Safety Between Fimasartan and Linagliptin in Healthy Male Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 39 (actual)
• Sponsor: Boryung Pharmaceutical Co., Ltd · Industry
• Sex: Male
• Age: 19 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate pharmacokinetic interactions and safety between fimasartan and linagliptin in healthy male volunteers.

Detailed description

This is an open-label, randomized, multiple-dose, two-period and single-sequence study to evaluate the pharmacokinetics and safety.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	(fimasartan or linagliptin) x 7days	Part A: fimasartan, Part B: linagliptin
DRUG	(fimasartan and linagliptin) x 7days	Part A \& Part B: Co-administration of fimasartan and linagliptin

Timeline

• Start date: 2017-08-14
• Primary completion: 2017-10-13
• Completion: 2017-11-21
• First posted: 2017-08-15
• Last updated: 2018-01-18

Locations

1 site across 1 country: South Korea